Literature DB >> 10210326

Establishment and characterization of a mouse strain (TLL) that spontaneously develops T-cell lymphomas/leukemia.

B Eriksson1, A S Johansson, G Roos, G Levan, D Holmberg.   

Abstract

In this study, a mouse strain (TLL) that spontaneously develops T-cell lymphomas/leukemia with an early onset and high incidence was established and characterized. All tumors analyzed were found to express the alpha,beta T-cell receptor, and the majority of them had a mature, CD3+CD4+CD8- immunophenotype. In a few cases, tumors with a more immature CD3+CD4+CD8+ phenotype were isolated. Expanded phenotyping using a broad panel of lymphocyte differentiation markers confirmed the mature T-cell phenotype of the tumors. Histologic and cell cycle analysis of the tumors revealed an aggressive lymphoblastic malignancy with a very high proliferation rate and widespread engagement of bone marrow and lymphoid as well as nonlymphoid organs. Thus, the TLL mouse strain represents a unique model for the analysis of the oncogenesis and progression of mature T-cell tumors and for the development of therapeutic measures to combat such tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210326     DOI: 10.1016/s0301-472x(99)00003-x

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  2 in total

1.  Retroviral insertions in the VISION database identify molecular pathways in mouse lymphoid leukemia and lymphoma.

Authors:  Keith C Weiser; Bin Liu; Gwenn M Hansen; Darlene Skapura; Kathryn E Hentges; Sujatha Yarlagadda; Herbert C Morse Iii; Monica J Justice
Journal:  Mamm Genome       Date:  2007-10-10       Impact factor: 2.957

2.  Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice.

Authors:  Silke H Raffegerst; Gabriele Hoelzlwimmer; Sandra Kunder; Josef Mysliwietz; Leticia Quintanilla-Martinez; Dolores J Schendel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.